Zobrazeno 1 - 10
of 67
pro vyhledávání: '"L. Curreli"'
Autor:
E Proto, Carlo Mulas, Antonio Testa, Mario Airoldi, D Dessi, Cesare Bumma, Giorgio Tore, B Lampis, Massimo Ghiani, L. Curreli, P. Lai, Elena Massa, Giovanni Mantovani, Gabrio Cadeddu, Vittorio Gebbia, A Bianchi, Paolo Contu
Publikováno v:
Cancer Immunology, Immunotherapy. 47:149-156
We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interle
Autor:
W Orrù, Mauro Giovanni Carta, Giovanni Mantovani, A Bianchi, Marco Sorrentino, N. Rudas, Bernado Carpiniello, Giorgio Astara, L. Curreli, B Lampis
Publikováno v:
Psycho-Oncology. 5:127-135
The aim of this study was to assess the impact of three different psychological interventions on the quality of life (QL) of elderly cancer patients with symptoms of anxiety and/or depression. Seventy-four patients were enrolled in the study. All wer
Autor:
Giorgio Astara, N. Rudas, Bernardo Carpiniello, Paolo Contu, B Lampis, A Bianchi, L. Curreli, Mauro Giovanni Carta, Giovanni Mantovani, W Orrù
Publikováno v:
Scopus-Elsevier
Our study belongs to the clinical trials in which the health-related quality of life (HQL) evaluation constitutes the primary endpoint. It was carried out with the aim of comparing the impact of three different types of psychological intervention, na
Autor:
L. Arru, A. Palmas, A. Uras, L. Curreli, A. Murgia, A. Bianchi, A. Noli, P. Lai, A. Gabbas, A. Calvisi, M. Murineddu, G. C. Latte, G. Piras, M. Monne, E. Gaviano
Publikováno v:
British journal of haematology. 129(6)
Summary There is strong evidence that altered immunological function entails an increased risk of lymphoma, although the current knowledge of aetiological factors for lymphomas is limited. The CTLA4 gene encodes a receptor that provides a negative si
Publikováno v:
Supportive Care in Cancer. 4:462-464
The aim of our study was to compare the impact of chemotherapy alone with that of chemotherapy plus immunotherapy on the quality of life (QL) of patients affected by advanced-stage malignancies (eight head and neck squamous-cell carcinomas, two melan
Publikováno v:
Anticancer research. 19(4C)
A single-institution, prospective, open crossover study was performed to compare the effectiveness and tolerability of transdermal fentanyl (TTS-F) vs intravenous (i.v.) ondansetron (OND), both combined with i.v. DEX, in the prevention of acute nause
Autor:
Mc Mudu, P. Lai, Elena Massa, Giovanni Mantovani, Antonio Macciò, Giorgio Astara, L. Curreli, G Succu, Massimo Ghiani, D Massa
Publikováno v:
Oncology reports. 6(2)
Despite the numerous studies demonstrating the effectiveness of epoetin a (human recombinant erythropoietin) versus placebo in cisplatin-induced anemia of cancer patients, data are lacking on the most effective doses and schedules of administration o
Autor:
E Proto, L. Curreli, S. Esu, G Succu, D Dessi, P. Lai, Giovanni Mantovani, Carlo Mulas, G. Cadeddu, Antonio Macciò, Giorgio Tore, Massimo Ghiani, D Massa
Publikováno v:
Oncology Reports.
The aims of the present open, randomized, single-blind (patient), single institution, phase II study were: i) to compare the therapeutic effectiveness and toxicity of two dosages and schedules of ifosfamide (IFO) in combination with cisplatin (CDDP)
Autor:
Antonio Macciò, Massimo Ghiani, L. Curreli, Paolo Contu, B Lampis, Giovanni Mantovani, A Bianchi
Publikováno v:
Scopus-Elsevier
A phase III, single-institution, open, prospective, randomized, parallel study was carried out on head and neck cancer patients to compare a combination of low-dose (20 mg q.i.d.) oral metoclopramide (M) + i.m. Dexamethasone (D) with an oral 5-HT3-Re
Autor:
A Bianchi, Elena Massa, M. C. Santona, Massimo Ghiani, E Proto, B Lampis, Giorgio Astara, Gebbia, Francesco Cossu, L. Curreli, Giovanni Mantovani, D Dessi
Publikováno v:
International Journal of Oncology.
We designed an open, non-randomized, phase II clinical study to assess as the first endpoint the feasibility of sparing surgery and of preserving organ/function by using neoadjuvant chemotherapy (NAC) laryngeal cancer patients, and, as the second end